Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

120 clinical studies listed.

Filters:

Prediabetes

Tundra lists 120 Prediabetes clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT07833397

Moringa Leaf Powder for Prediabetes

The goal of this clinical trial was to learn whether Moringa oleifera leaf powder could lower fasting blood glucose in adults aged 25 to 55 years with prediabetes. It also assessed unwanted health effects during the intervention. The main questions it aimed to answer were: * Does taking Moringa oleifera leaf powder daily for 90 days lower fasting blood glucose compared with a placebo? * What unwanted health effects occur while participants take Moringa oleifera leaf powder or placebo? Researchers compared Moringa oleifera leaf powder with matching placebo capsules that contained no Moringa. Participants: * Were randomly assigned to receive Moringa oleifera leaf powder or placebo * Took six 400-mg capsules daily, as two capsules three times a day after meals, for 90 days * Measured and recorded fasting blood glucose at baseline and every 3 days during the study * Reported adherence and any unwanted health effects

Gender: All

Ages: 25 Years - 55 Years

Updated: 2026-11-18

1 state

Prediabetes
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
NOT YET RECRUITING

NCT07878806

Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs

The goal of this study is to learn whether FUERTE (Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs) can facilitate referrals of Hispanic men with prediabetes to the Diabetes Prevention Program (DPP) and support their continued engagement in the program. The main questions it aims to answer are: Does implementation of the FUERTE strategy increase the number of DPP-eligible Hispanic men who are referred to and enrolled in the DPP? Does implementation of the FUERTE strategy improve engagement in the DPP and result in greater improvements in weight and hemoglobin A1C among Hispanic men participating in the program? FUERTE consists of three components: 1. Information sessions for healthcare providers to increase awareness of the DPP. 2. Text messages sent to DPP-eligible Hispanic men reminding them of appointments and encouraging discussions about prediabetes with healthcare providers. 3. Interactive WhatsApp group messages for Hispanic men referred to the DPP, providing tailored content and discussion prompts related to each core DPP session. Participants will: * Complete a survey before enrolling in the DPP. * Complete a survey after completing the DPP. * Those participating post-implementation of FUERTE will (1) receive text-messages, reminding them of their appointments and encouraging discussions about prediabetes with providers, and (2) receive interactive group-messages, delivered through WhatsApp, to supplement the standard of care DPP with tailored topics and prompts.

Gender: MALE

Ages: 18 Years - 99 Years

Updated: 2026-11-18

1 state

Prediabetes
RECRUITING

NCT07389005

Exercise, Chronotype, and Prediabetes

The goal of this clinical trial is to find out whether exercising at the right time of day, based on a person's natural body clock, leads to greater health benefits in people living with prediabetes. The main question it aims to answer is whether doing a single session of exercise in the morning or in the evening affects how the body handles sugar differently in adults with prediabetes who have an extreme natural body clock. This will be done by comparing three conditions (no-exercise, morning exercise, and evening exercise) within the same participant. Each condition will be tested on a different day, with at least 14 days between the test days. During the no-exercise test days, participants will come to the study centre and will only be allowed to do sedentary activities (e.g. office work, reading, or screen time). During the morning exercise test days, participants will perform an exercise session at 9:00 am that involves short periods of very hard effort followed by short rest periods. Whereas for the evening exercise test days, the same type of exercise will be performed at 5:00 pm.

Gender: All

Ages: 19 Years - 75 Years

Updated: 2026-11-16

Prediabetes
Overweight , Obesity
COMPLETED

NCT07937449

The Efficacy and Safety of DLBS3233 in Adults With Prediabetes

This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy. DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.

Gender: FEMALE

Ages: 18 Years - 65 Years

Updated: 2026-11-16

2 states

Prediabetes
RECRUITING

NCT07804680

Cardiorespiratory Fitness, Handgrip Strength, and Cardiometabolic Health in Obese Children With or Without Autism Spectrum Disorder: a Retrospective Cohort Study

The goal of this observational study is to evaluate cardiorespiratory and muscular fitness in children with obesity, with and without autism spectrum disorder (ASD), and examine how fitness relates to body measurements, body composition, and cardiometabolic health. The main questions it aims to answer are: * Do children with and without ASD differ in cardiorespiratory fitness and handgrip strength? * Are fitness levels related to body composition and measures of cardiometabolic health? Researchers will compare children with ASD to children without ASD to see if there are differences in fitness, body composition, and cardiometabolic health. Participants will have information from their medical records reviewed, including: * Cardiorespiratory fitness and handgrip strength test results * Height, weight, BMI, and body composition measurements * Blood test results, including HbA1c and cholesterol levels * Age, sex, and other demographic information

Gender: All

Ages: 6 Years - 18 Years

Updated: 2026-11-13

1 state

Autism Spectrum Disorder (ASD)
Cardiometabolic Health Indicators
Cardiometabolic Risk Factors
+2
COMPLETED

NCT07210684

Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes

The goal of this clinical trial is to learn if Dihydroberberine (DHB) supplementation affects adults with pre-diabetes. The main questions it aims to answer are: Does DHB supplementation increase the concentration of GLP-1 in the blood? Does DHB supplementation affect appetite, mood, and energy levels? Does DHB supplementation affect body weight, blood sugar control and insulin? Researchers will compare DHB supplementation to a placebo (a look-alike substance that contains no drug) to see if DHB has any effect. Participants will: Take DHB or a placebo every day for 6 weeks. Participate in tests to measure GLP-1 levels, blood glucose, insulin and other markers. Have their continuous blood sugar profiles (with CGMs) monitored to see how much time their blood sugar spends in a healthy range. Rate their appetite, mood, and energy levels using a visual analog scale.

Gender: All

Ages: 35 Years - 65 Years

Updated: 2026-11-13

1 state

Prediabetes
RECRUITING

NCT07149064

Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes

The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is: What is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-12

1 state

Normoglycemia
Prediabetes
Glycemic Control
RECRUITING

NCT06025292

Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults

We will be directly comparing a high-quality protein diet composed primarily of lean pork loin (PORK) to a lower-quality plant-based protein diet (PLANT) in individuals with prediabetes on muscle and whole-body protein turnover and glucose regulation.

Gender: All

Ages: 40 Years - 65 Years

Updated: 2026-11-06

1 state

Hyperglycaemia (Non Diabetic)
Prediabetes
ENROLLING BY INVITATION

NCT07209527

Truway Diagnostic Tools in Primary Care

This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings. Conducted as a prospective interventional trial, 200 participants will be assigned to use these devices versus standard care over a 6-month period. The primary outcome is improved diagnostic accuracy and patient outcomes. The study, led by Truway Health, Inc., aims to enhance accessible healthcare solutions starting at a New York site, with potential expansion to Miami.

Gender: All

Updated: 2026-11-05

1 state

Chronic Disease
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Hypertension
+6
NOT YET RECRUITING

NCT07904962

Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes

The goal of this clinical trial is to evaluate how different time ratios of aerobic and resistance training affect blood glucose levels and physical health in adults aged 50 years and older with prediabetes. Researchers will compare three combined exercise programs with aerobic-to-resistance training time ratios of 3:1, 1:1, and 1:3 with a health education control group. Participants in the exercise groups will take part in supervised training three times per week for 12 weeks. Each session will include approximately 60 minutes of aerobic and resistance exercise, with the amount of time spent on each type of exercise differing according to the assigned group. Participants will complete health assessments before and after the 12-week intervention. The main outcome of interest is glycated hemoglobin (HbA1c), which reflects average blood glucose levels over the previous 2 to 3 months. Participants in the control group will receive standardized health education and will not take part in the study-provided structured exercise program during the 12-week intervention period.

Gender: All

Ages: 50 Years - Any

Updated: 2026-11-03

1 state

Prediabetes
COMPLETED

NCT04465721

TREAT to Improve Cardiometabolic Health

Over half of American adults have overweight or obesity and are at high risk of developing type 2 diabetes and cardiovascular diseases. Although caloric restriction has many health benefits, it is difficult to sustain overtime for most people. Time restricted eating (TRE), a novel type of intermittent fasting, facilitates adherence to the intervention and results in weight loss and improvement of metabolism. The investigators propose to examine the efficacy of self-monitoring and TRE (10-h/d) vs. self-monitoring and habitual prolonged eating duration (HABIT) (13 hours/d) on weight loss and body composition, metabolic function and circadian biology, in metabolically unhealthy adults aged 50 to 75 y old, with overweight or obesity. The investigators hypothesize that TRE, compared to habitual long duration of eating, will decrease cardiovascular risk burden.

Gender: All

Ages: 50 Years - 75 Years

Updated: 2026-11-02

1 state

Overweight and Obesity
Prediabetes
ACTIVE NOT RECRUITING

NCT05023993

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a dietary supplement which is similar to vitamin B3. Information collected in this study may help the future development of regimens to improve metabolic outcomes such as muscle health and insulin resistance (when the body is not normally responding to insulin) in childhood cancer survivors.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-30

1 state

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Prediabetes
NOT YET RECRUITING

NCT07846319

Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality

Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, per protocol criteria based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at UBS (Primary Health Care Units) in Afogados da Ingazeira, during the 12 months post-implementation, compared to a reference value estimated from a historical 12-month period in the same municipality. Methodology: Pragmatic, quasi-experimental, single-arm effectiveness and implementation study with a historical comparator. In each period, the analytic population will be defined by eligibility on the respective index date. In the historical period, data will estimate the reference proportion of the primary outcome and historical values of applicable secondary outcomes. In the post-intervention period, individuals eligible on the index date will be followed for 12 months via care records. Individuals who become eligible after the post-intervention index date may receive care actions under the strategy and be included in operational, implementation, and exploratory analyses, but not in outcome denominators fixed at the index date. The study will take place in Afogados da Ingazeira, Pernambuco, covering all 15 UBS with an affiliated Family Health Team. Research-specific technological components will incur no additional cost to the municipality. ARISE comprises two components: 1. Digital analytics layer, built on the existing epHealth infrastructure. It uses structured data from e-SUS PEC to apply predefined T2DM screening eligibility rules. Identified individuals appear in operational lists and may generate alerts for UBS managers and community health workers, supporting visits, scheduling, test requests, follow-up, and patient return. It may also flag: delays over 60 days between test request and completion, availability of lab results, and need for active case-finding. No test, diagnosis, prescription, referral, or treatment is automated; clinical decisions remain with APS professionals and managers. 2. Professional training. UBS managers, community health workers, physicians, nurses, and nursing technicians will be trained on the PCDT-DM2 and ARISE workflows, before the digital layer's activation. Professionals are research participants only for evaluating educational impact, acceptability, and usability, provided they attend the relevant training and sign the Informed Consent Form (ICF). Training participation is independent of research participation; declining data use carries no functional or institutional penalty. A census-based approach will define population size. The primary analysis includes all individuals eligible on the post-intervention index date; final numbers depend on municipal database findings. Power calculations covered 8,000-30,000 eligible individuals and historical T2DM diagnosis proportions of 0.80%-0.90%. A population of \~14,000-15,000 eligible individuals yields \~80% power to detect a \~25% relative increase, for historical proportions of 0.85%-0.90%. For professional-related components, a census approach covers all eligible categories per the updated roster of active professionals directly involved. Statistical analysis: The post-intervention proportion of confirmed T2DM diagnosis will be compared to the historical reference using a two-tailed one-proportion test (5% significance level). Point estimates, 95% CIs, absolute differences, and proportion ratios (where applicable) will be reported. Adjusted analyses may use logistic regression. Change in professionals' knowledge will be analyzed via paired intra-individual pre/post-training score differences. RE-AIM indicators will be mainly descriptive. Acceptability, training reaction, and workflow perception blocks will be scored separately (1-5). Usability will be assessed via the System Usability Scale (0-100) among professionals who directly used the digital component. The study was approved by the Research Ethics Committee (REC), CAAE n. 00260026.5.0000.5330, approval opinion n. 8.705.723. Primary outcome: Confirmed T2DM diagnosis during the observation period, treated as a binary individual indicator.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-30

2 states

Diabetes Mellitus (Type 2)
Prediabetes
NOT YET RECRUITING

NCT07903870

Efficacy of the pA1c®HI Postbiotic in Metabolic Regulation in Healthy Individuals With Hyperglycemia

This study will evaluate the effects of pA1c®HI, a heat-inactivated postbiotic derived from the bacterium Pediococcus acidilactici, on blood glucose regulation and other aspects of metabolic health in adults with elevated blood glucose levels who do not have diagnosed diabetes. The study will include approximately 100 adults aged 18 to 80 years with glycated hemoglobin (HbA1c) levels of 5.7% to less than 6.5%, a range consistent with prediabetes. A postbiotic is a preparation of inactivated microorganisms and/or their components that may provide health benefits. pA1c®HI does not contain live bacteria. This is an open-label, single-group study. All participants will take one capsule of pA1c®HI daily for 12 weeks. There is no placebo or separate control group. Researchers will compare measurements taken before and after the intervention to assess changes over time. Participants will continue their usual medical care and previously established lifestyle recommendations. The study will include assessments at the beginning and end of the intervention. These will include blood tests, measurements of body weight and other physical characteristics, questionnaires, and continuous glucose monitoring for 14 days at each assessment period. Participants will also provide stool samples for analysis of gut microbiota composition. Blood tests will assess glycated hemoglobin, fasting glucose, insulin-related markers, blood lipids, liver function, and other parameters. Researchers will also measure glucagon-like peptide-1 (GLP-1), a hormone involved in blood glucose regulation, including its response to a mixed meal. The main objective is to evaluate changes in HbA1c after 12 weeks of daily pA1c®HI supplementation. Other objectives include assessing changes in glucose levels and variability, insulin resistance markers, blood lipids, GLP-1 responses, gut microbiota composition, and body measurements. The study will also assess adherence to supplementation and monitor safety and tolerability. The findings will help researchers understand the potential effects of pA1c®HI on metabolic health in adults with elevated blood glucose levels. Because the study does not include a placebo or control group, changes observed during the study cannot be attributed to the postbiotic with the same certainty as in a controlled trial.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2026-10-29

Hyperglycemias
Prediabetes
RECRUITING

NCT07372729

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among metabolically at-risk people with overweight/obesity, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-29

3 states

Overweight , Obesity
Prediabetes
High-normal Blood Pressure
+1
RECRUITING

NCT07888257

LIfestyle MEtabotype Study B (LIME-B)

Glycemic responses vary significantly among individuals, even when consuming identical foods or meals, but the factors predicting individual glucose responses to food intake remain poorly investigated. The aim of the LIfestyle MEtabotype (LIME) study is to identify lifestyle-related and mechanistic factors which predict individual postprandial glucose fluctuations in individuals with different glycemic status (prediabetes, type 2 diabetes \[T2D\] and absence of prediabetes or T2D), using comprehensive lifestyle characterization and metabolic, molecular and neurocognitive phenotyping. As part of this phenotyping, the LIME study also investigates the role of ketone bodies. Individuals with insulin resistance, prediabetes or T2D often show impaired cerebral glucose utilization. Ketone bodies, such as β-hydroxybutyrate (βHB) may serve as an alternative energy source for the brain. However, how exogenous βHB affects neurocognitive processes and decision-making in individuals with different glycemic status remains poorly understood. This record describes module B of the LIME study. Module B investigates the effects of a single dose of exogenous βHB, compared with a carbohydrate-based placebo drink, on brain structure and function, decision-making behavior and physiological and metabolic responses. Module A comprises a comprehensive lifestyle and metabolic characterization of the same participants and is registered separately as an observational study (NCT07868601). Data from both modules will be integrated in joint analyses.

Gender: All

Ages: 40 Years - 75 Years

Updated: 2026-10-28

Nutritional and Metabolic Diseases
Prediabetes
Type 2 Diabetes
NOT YET RECRUITING

NCT07639593

Trial of CGM Technology in Persons Living With Prediabetes

Continuous glucose monitor (CGM) technology has become increasingly prevalent in the population and has the ability to transform care of patients living with prediabetes. While the technology was initially utilized primarily by patients living with type 1 diabetes using insulin pump therapy, it has become more widely used as part of care in patients living with type 1 or 2 diabetes on any kind of insulin therapy.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-23

1 state

Prediabetes
ACTIVE NOT RECRUITING

NCT07450118

Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans

This nested pilot Randomized Clinical Trial will determine whether the Diabetes Prevention Program (DPP) enhanced with evidence-based sleep health and time restricted eating interventions ("DPP++") is more effective than the DPP alone for improving metabolic and cardiovascular metrics in 40 overweight/obese adults with prediabetes.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-22

1 state

Prediabetes
NOT YET RECRUITING

NCT07890740

Continuous Glucose Monitoring and Dietary Self-Management in Adults in Namwon

This study will test whether adding a continuous glucose monitoring (CGM) device, which shows personal glucose patterns, improves dietary self-management over the first 6 weeks. Both groups receive the same digital health program, standardized education, and support for setting behavioral goals. It will include 860 residents of Namwon, Republic of Korea, aged 40 years or older who have elevated fasting glucose or documented type 2 diabetes diagnosis or treatment. After screening, participants will be assigned by chance to one of two groups of 430. Assignment is preferably on the first screening visit but may occur later. The actual assignment date is Day 0. The device group will use one CGM sensor for approximately 10 days after assignment. The wait-list control group will receive the same education and behavioral goal-setting support during the first 6 weeks, without a CGM device. Researchers will compare dietary self-management scores at week 6, before the control group receives a sensor. After the week 6 assessment and data lock, the control group will also be offered a sensor so that all eligible randomized participants have an opportunity to use the device. This later offer is not the main intervention comparison. Week 12 assessments provide exploratory follow-up after both groups have been offered a device. Researchers will also assess application use, body weight, waist circumference, blood pressure, and safety. The research team will not change medicines based on sensor readings, and usual medical care will continue.

Gender: All

Ages: 40 Years - Any

Updated: 2026-10-22

1 state

Prediabetes
Dietary Self-Management
Diabetes Mellitus, Type 2
RECRUITING

NCT07225218

New T-UP: Engaging Vulnerable Students in Diabetes Prevention

The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.

Gender: All

Ages: 17 Years - 25 Years

Updated: 2026-10-21

1 state

Prediabetes
Type 2 Diabetes
RECRUITING

NCT07289880

Efficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes

This study will implement a four-week dietary intervention among middle-aged and older adults with pre-diabetes. Participants assigned to the intervention arm will replace their usual cooking oil with diacylglycerol (DAG) oil, while those in the control arm will consume colza oil. All other lifestyle behaviors will be maintained without modification. The trial will determine the impact of DAG oil consumption on glycemic regulation, lipid metabolism, and body composition in this high-risk population.

Gender: All

Ages: 40 Years - 75 Years

Updated: 2026-10-21

1 state

Prediabetes
NOT YET RECRUITING

NCT07815236

Diabetes Prevention Through Genetics, Familial History and Behavior Change

The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes. It will also learn about the effects of this approach on family members' health. The main questions it aims to answer are: * Does adding family health history collection and family participation to the DPP improve session attendance compared to standard DPP? * Does this family-centered approach lead to greater weight loss and HbA1c (blood sugar) reduction compared to standard DPP? * Do health improvements extend to participants' family members, and what factors explain differences in family-level outcomes? Researchers will compare an adapted DPP with a family component to the standard DPP (individual-focused) to see if involving family members improves diabetes prevention outcomes. Participants will: * Be assigned to one of two groups: adapted DPP with family sessions, or standard DPP * If assigned to the adapted DPP, complete a family health history using the Center for Disease Control and Prevention's (CDC) My Family Health Portrait tool and attend 6 additional sessions with family members focused on personalized risk communication * Attend regular checkups to measure weight and HbA1c at 6 and 12 months * Have session attendance tracked throughout the program * Family members of participants may also be asked to complete health assessments to measure any changes in their own health behaviors

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-10-20

Prediabetes
Weight Loss
ENROLLING BY INVITATION

NCT07868432

Glycemic Impact of NNS Via the Gut Microbiome

This pilot study will evaluate the feasibility and acceptability of a 30-day sucralose intervention among adults with prediabetes. Participants will consume six commercial sucralose (Splenda®) packets daily for 30 days while wearing a blinded continuous glucose monitor (CGM). Oral glucose tolerance tests (OGTTs) with blood draws will be performed at baseline and after 30 days to assess glucose incremental area under the curve (iAUC). Stool samples will also be collected to assess the feasibility of microbiome sample collection for future studies. The study will generate preliminary data to inform the design of a larger randomized clinical trial examining the effects of non-nutritive sweeteners on glucose homeostasis and the gut microbiome.

Gender: All

Ages: 35 Years - Any

Updated: 2026-10-09

1 state

Prediabetes
RECRUITING

NCT07868601

LIfestyle MEtabotype Study A

Glycemic responses vary significantly among individuals, even when consuming identical foods or meals, but the factors predicting individual glucose response to food intake remain poorly investigated. The aim of the LIfestyle MEtabotype study (LIME) observational study is to identify lifestyle-related and mechanistic factors which predict individual postprandial glucose fluctuations in individuals with different glycemic status (prediabetes, type 2 diabetes \[T2D\], and absence of prediabetes or T2D). To address this aim, the study will conduct a comprehensive lifestyle characterization and metabolic, molecular and neurocognitive phenotyping during study center visits and a dietary, glucose, sleep and activity monitoring during the observational phase.

Gender: All

Ages: 40 Years - 75 Years

Updated: 2026-10-09

1 state

Nutritional and Metabolic Diseases
Prediabetes
Type 2 Diabetes